Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oncorine Combined with TACE for Stage IIIa HCC with Portal Vein Thrombosis
NCT05872841Phase 2Unknown
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Jun 2023
- Primary completion
- Dec 2024
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
01
Overview
A Phase 2 trial of Oncorine in hepatocellular carcinoma (HCC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Status: unknown.
02
Drugs
Oncorine
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05872841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05872841.